Bioprinting towards Physiologically Relevant Tissue Models for Pharmaceutics.
Improving the ability to predict the efficacy and toxicity of drug candidates earlier in the drug discovery process will speed up the introduction of new drugs into clinics. 3D in vitro systems have significantly advanced the drug screening process as 3D tissue models can closely mimic native tissues and, in some cases, the physiological response to drugs. Among various in vitro systems, bioprinting is a highly promising technology possessing several advantages such as tailored microarchitecture, high-throughput capability, coculture ability, and low risk of cross-contamination. In this opinion article, we discuss the currently available tissue models in pharmaceutics along with their limitations and highlight the possibilities of bioprinting physiologically relevant tissue models, which hold great potential in drug testing, high-throughput screening, and disease modeling.
Engineering Science and Mechanics, The Pennsylvania State University, State College, PA 16802, USA; Department of Pharmacology, Nanchang University, Nanchang, Jiangxi, China.
Weijie
W
Peng
The Jackson Laboratory of Genomics Medicine, Farmington, CT 06032, USA.
Derya
D
Unutmaz
Engineering Science and Mechanics, The Pennsylvania State University, State College, PA 16802, USA; The Huck Institutes of the Life Sciences, The Pennsylvania State University, State College, PA 16802, USA; Materials Research Institute, The Pennsylvania State University, State College, PA 16802, USA. Electronic address: ito1@psu.edu.
Ibrahim T
IT
Ozbolat
D000818:Animals; D062028:Bioprinting; D055808:Drug Discovery; D057166:High-Throughput Screening Assays; D006801:Humans; D008954:Models, Biological; D046888:Tissue Array Analysis
bioprinting; drug screening; high-throughput assays; organ-on-chip models